Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 5/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29080010 | 0.84 | PTGS1 (0.40) | PTGS1PTGS2MEN1KMT2ANOTUM | |
| SCHEMBL17073804 | 0.80 | NPC1 (0.43) | PTGS1PTGS2CA1CA9MEN1 | |
| SCHEMBL13923616 | 0.80 | ALDH1A1 (0.40) | PTGS2CA1CA9MEN1KMT2A | |
| SCHEMBL13492165 | 0.80 | PTGS1 (0.41) | PTGS1PTGS2CA1CA9PDE3B | |
| SCHEMBL13492167 | 0.80 | HTR2C (0.36) | CA1CA9MEN1KMT2A | |
| SCHEMBL3214101 | 0.79 | BACE1 (0.42) | PTGS1PTGS2NOTUM | |
| SCHEMBL979881 | 0.79 | KMT2A (0.45) | PTGS1PTGS2CA1CA9MEN1 | |
| SCHEMBL2165399 | 0.76 | MAPT (0.39) | CA1CA9PDE3BPDE3ANOTUM | |
| SCHEMBL7618292 | 0.76 | PTGS2 (0.42) | PTGS1PTGS2CA1CA9RAB9A | |
| SCHEMBL30692648 | 0.76 | CA1 (0.48) | PTGS1CA1CA9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586618-B2 | Furanone compounds and lactam analogues thereof | BIOSIGNAL LIMITED (AU) | 2013-11-19 | — | — | US | disclosed |
| US-8586618-B2 | Furanone compounds and lactam analogues thereof | BIOSIGNAL LIMITED (AU) | 2013-11-19 | — | — | US | disclosed |
| US-20100035948-A1 | Furanone compounds and lactam analogues thereof | UNILEVER PLC (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035948-A1 | Furanone compounds and lactam analogues thereof | UNILEVER PLC (GB) | 2010-02-11 | — | — | US | disclosed |
| US-20100035948-A1 | Furanone compounds and lactam analogues thereof | UNILEVER PLC (GB) | 2010-02-11 | — | — | US | disclosed |
| WO-2008040097-A1 | FURANONE COMPOUNDS AND LACTAM ANALOGUES THEREOF | BIOSIGNAL LIMITED (AU) | 2008-04-10 | — | — | WO | disclosed |
| EP-1397364-B1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | LILLY CO ELI (US) | 2007-07-25 | — | — | EP | disclosed |
| US-7087626-B2 | Pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY | 2004-06-03 | — | — | US | disclosed |
| EP-1397364-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | TGFBR1, SMAD3, TGFBR2 | PTGS1 77/4885PTGS2 596/4885CA1 3985/4885 |
| US-20100035948-A1 | Furanone compounds and lactam analogues thereof | FDPS, CYP2C19, MRPL21 | PTGS1 288/4885PTGS2 267/4885CA1 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.